The following should be carefully reviewed prior to submission.
NEW September 6, 2017: TOP Guidelines
Please ensure that your manuscript adheres to the AHA Journals' implementation of the Transparency and Openness Promotion (TOP) Guidelines (available online at http://www.ahajournals.org/
Updated June 27, 2018: Reporting Standards for Preclinical Studies of Stroke Therapy:
To improve quality of preclinical studies, a simple checklist requesting reporting of randomization procedures, blinding, a priori definition of inclusion and exclusion, and so on was implemented in 2011. A checklist has been developed as a prerequisite for every publication involving animal treatment experiments submitted to Stroke. As of June 18, 2018, this checklist has been incorporated as a form to be completed during the online submission process and published as a online supplement with every article. The checklist is evaluated by editors and reviewers and is intended to improve reporting of key characteristics of the overall scientific quality, relevant components of quality such as definition of inclusion and exclusion criteria, statement of randomization methods, allocation concealment, and reporting of postrandomization exclusion of animals. A more explanatory table is provided to aid interpretation, application, and reporting of necessary criteria.
See the editorial "Reporting Standards for Preclinical Studies of Stroke Therapy," http://dx.doi.org/10.1161/STROKEAHA.116.013643 for details.
Guidelines for Clinical Trials:
In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (Circulation. 2005;111:1337 and http://content.nejm.org/cgi/content/full/NEJMe078110 ), all clinical trials in Stroke must be registered in a public trials registry at or before the onset of participant enrollment. This requirement applies to all clinical trials that begin enrollment after July 1, 2005 and applies to all clinical trials, including Phase 1 studies. Any research study that prospectively assigns human participants or groups of humans to one or more health-related intervention(s) to evaluate the effects on health outcomes is considered a clinical trial. The special report, The Proposed Rule for U.S. Clinical Trial Registration and Results Submission published in The New England Journal of Medicine, can be consulted for the guidance.
Those who are uncertain whether their trial meets the ICMJE definition of a clinical trial should err on the side of registration if they wish to seek publication.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, and managed by a not-for-profit organization. The registry must include the following information: a unique identifying number, a statement of the intervention(s), study hypothesis, definition of primary and secondary outcome measurements, eligibility criteria, target number of subjects, funding source, contact information for the principal investigator, and key dates (registration date, start date, and completion date).
The registry sponsored by the United States National Library of Medicine (http://www.clinicaltrials.gov ) meets these requirements and is recommended by the editors.
Other registries are acceptable if they meet these requirements. In addition to http://www.clinicaltrials.gov, the following registries are recommended by the ICMJE:
In accordance with the ICMJE’s recommendation, we will also accept registration of clinical trials in any of the primary registers that participate in the World Health Organization’s International Clinical Trial Registry Platform. Primary registers are WHO-selected registers managed by not-for-profit entities that will accept registrations for any interventional trials, delete duplicate entries from their own register, and provide data directly to the WHO. Please note that registration in any WHO partner registers is insufficient.
The authors will be requested to provide the exact URL and unique identification number for the trial registration at the time of submission. Since this information will be published, we ask that you include a fourth heading in your abstract: "Clinical Trial Registration Information". Please list the URL, as well as the unique identifier, for the publicly accessible web site on which the trial is registered in this section.
Clinical trial reports should also comply with the Consolidated Standards of Reporting Trials (CONSORT) and include a flow diagram presenting the enrollment, intervention allocation, follow-up, and data analysis with number of subjects for each (http://www.consort-statement.org/?o=1011). Please also refer specifically to the CONSORT Checklist of items to include when reporting a randomized clinical trial.
Results posted in the same clinical trials registry in which the primary registration resides will not be considered prior publication if they are presented in the form of a brief abstract (≤500 words) or a table.
Guidelines for Meta-Analyses:
Any submitted meta-analysis or systematic review should follow the PRISMA or MOOSE guidelines. Please state in the methods section which guideline the authors followed. If you use the PRISMA guidelines, 1) please include a copy of the PRISMA checklist as a related manuscript file (not for publication); and 2) include a flow diagram in your manuscript or supplemental data. The authors should use journal formatting for abstracts.
Note that systematic reviews and meta-analyses will be sent to a statistical reviewer during the course of review.
See “Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting,” JAMA. 2000;283:2008-2012.
See the PRISMA statement http://www.prisma-statement.org/.
Guidelines for Human Phenotype–Genotype Association or Linkage Studies:
- Reporting issues:
- Report process for selecting genes and SNPs.
- Report Hardy-Weinberg statistics or p-values and method of calculating same.
- Refer to existing public domain websites for the Human Gene Ontology name and the rs number for SNPs.
- Describe genotyping methods. If numerous primers have been used, please include them in an online supplement.
- False positive and false negative concerns. Given well-described problems with both false positive and false negative associations, phenotype-genotype association studies should meet some or all of the criteria below:
- Phenotype is clearly defined, is heritable, and if a quantitative phenotype is reported, reproducibility data are provided.
- The sample size is adequate to detect a SNP or haplotype with a modest effect. For genotype-trait associations, provide an estimate of the effect size that could be detected with power 0.80 or higher with the allele frequency and sample size reported.
- Since multiple statistical testing methods are frequently used in genotyping-phenotyping studies, please include specifics of the primary model(s) tested. Nonessential secondary models may be published as electronic data supplements. Clinically relevant confounders should be included in multivariable models or residuals.
- Review criteria for human linkage studies. Manuscripts should include the following:
- Identifying plausible candidate genes under the linkage peak.
- Follow-up fine mapping to narrow the region of linkage, and/or genotyping some of the candidate genes under the linkage peak.
- Replication data from another sample.
Guidelines for Genomic and Proteomic Studies:
- Preparation of Data Submitted: Data should follow the MIAME checklist (for more information see http://www.mged.org/Workgroups/MIAME/miame_checklist.html ).
- Accessibility of Data: Authors of papers that include genomic, proteomic, or other high-throughput data are required to make their data easily accessible for the reviewers and the editors during the review process.
- You may submit your data to the NCBI gene expression and hybridization array data repository (GEO, http://www.ncbi.nlm.nih.gov/geo/) and provide the GEO accession number; or
- You may provide a link to a secure or publicly accessible website which hosts the data. Prior to publication, the data must be submitted and an accession number obtained. Access to the information in the database must be available at the time of publication. GEO has a web-based submission route, suitable for a small number of samples, or a batch submission tool (called SOFT). GEO is accessible from http://www.ncbi.nlm.nih.gov/geo/. The submission FAQ is available at http://www.ncbi.nlm.nih.gov/projects/geo/info/faq.html.
Guidelines for Proteins and Nucleic Acid Sequences:
Newly reported nucleotide or protein sequences must be deposited in GenBank or EMBL databases, and an accession number must be obtained. Access to the information in the database must be available at the time of publication. Authors are responsible for arranging release of data at the time of publication. The authors must also provide a statement in the manuscript that this sequence has been scanned against the database and all sequences with significant relatedness to the new sequence identified (and their accession numbers included in the text of the manuscript).
National Center for Biotechnology Information
8600 Rockville Pike, Building 38A
Bethesda, MD 20894
Tel: (301) 496-2475
On the web at: http://www.ncbi.nlm.nih.gov/Genbank/index.html
- EMBL Nucleotide Sequence Submissions
European Bioinformatics Institute
Hinxton, Cambridge CB10 1SD, UK
Tel.: 44-1223-494401; Fax: 44-1223-494472
On the web at: http://www.ebi.ac.uk
- DNA Data Bank of Japan
Center for Information Biology
National Institute of Genetics
Mishima, Shizuoka, 411, Japan
Tel.: 81-559-81-6853; Fax: 81-559-81-6849
On the web at: http://www.ddbj.nig.ac.jp
Submission to any data bank is sufficient to ensure entry in all.
Instructions for Authors Menu
|Article Types||Revised Manuscripts|
|General Preparation Instructions||Costs to Authors|
|How to Submit a Manuscript||Journal Policies|
|Tips for Submission||Submit Your Manuscript Now|